Reata Pharmaceuticals To Present Data From Pivotal Phase 2b Trial In Type 2 Diabetics With Chronic Kidney Disease

Rate This

1 Star2 Stars3 Stars4 Stars5 Stars
Loading ... Loading ...

Reata Pharmaceuticals announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes…

Reproduced under the Fair Use exception of 17USC107
avatar
type diabetes
2 years ago